What is the recommended rocuronium dose for rapid sequence intubation (RSI) in adults (including obese patients) and children, and how should dosing be adjusted for hepatic impairment, neuromuscular disorders, or malignant hyperthermia risk?

Rocuronium Dosing for Rapid Sequence Intubation

Standard Adult Dosing

For rapid sequence intubation in adults, administer rocuronium 0.6 to 1.2 mg/kg IV, with doses ≥1.2 mg/kg providing superior first-attempt intubation success, particularly when using direct laryngoscopy. 1

The FDA-approved dosing range is broad (0.6-1.2 mg/kg), but emerging evidence suggests higher dosing improves outcomes:

• Standard dose: 0.6 mg/kg provides intubation conditions in <2 minutes with 31 minutes of clinical relaxation 1
• Higher dose: 1.2 mg/kg achieves excellent intubating conditions in <2 minutes without cardiovascular adverse effects 1
• Optimal dose: ≥1.4 mg/kg demonstrates significantly higher first-attempt success (92.2% vs 88.1% with standard dosing) when using direct laryngoscopy, with no increase in adverse events 2

Evidence Quality Considerations

The 2023 Society of Critical Care Medicine guidelines suggest either rocuronium or succinylcholine for RSI (conditional recommendation, low-quality evidence) 3, while the 2025 Difficult Airway Society guidelines emphasize that neuromuscular blockade is superior to alternative strategies for successful intubation 4. However, neither guideline specifies optimal rocuronium dosing, making the FDA label and recent research critical for dose selection.

Obese Patients

In obese patients, dose rocuronium based on total body weight (TBW), not lean body weight (LBW).

For patients with BMI 25-34.9, TBW-based dosing (0.6 mg/kg) provides optimal intubation conditions, while LBW-adjusted dosing results in inadequate neuromuscular blockade and requires additional doses 5. The only exception is patients with normal BMI (18.5-24.9), where LBW-adjusted dosing may be acceptable 5.

Critical pitfall: Underdosing obese patients by using ideal body weight calculations leads to failed first attempts and need for rescue dosing.

Pediatric Dosing

For children, administer rocuronium 0.6 mg/kg based on total body weight. 1

Age-specific considerations:

• Sevoflurane induction: 0.45-0.6 mg/kg produces excellent intubating conditions within 75 seconds
• Halothane induction: 0.6 mg/kg achieves excellent conditions within 60 seconds
• Infants (28 days-3 months): Shortest time to maximum block
• Neonates (<28 days): Longest time to maximum block; lowest maintenance requirements
• Children (>2-11 years): Shortest duration of clinical relaxation; highest maintenance requirements

Rocuronium is NOT recommended for rapid sequence intubation in pediatric patients per FDA labeling 1, though it can be used for standard intubation.

Hepatic Impairment

Reduce rocuronium dose and extend dosing intervals in patients with hepatic impairment.

Rocuronium undergoes hepatic elimination, and liver dysfunction prolongs duration of action. While specific dose reductions are not provided in the FDA label, clinical monitoring with peripheral nerve stimulation is mandatory to guide dosing 1. Consider starting at the lower end of the dosing range (0.6 mg/kg) and monitoring recovery carefully before administering maintenance doses.

Neuromuscular Disorders

Exercise extreme caution and consider dose reduction in patients with neuromuscular disorders.

Patients with myasthenia gravis, Eaton-Lambert syndrome, or other neuromuscular conditions may exhibit:

• Enhanced sensitivity to rocuronium (requiring dose reduction)
• Prolonged recovery times
• Unpredictable responses

The FDA label specifically warns that dose adjustment should be considered in patients with anticipated potentiation or resistance to neuromuscular block 1. Use peripheral nerve stimulation monitoring to titrate dosing.

Malignant Hyperthermia Risk

Rocuronium is SAFE to use in patients with malignant hyperthermia (MH) susceptibility—it is NOT a triggering agent. 6, 7, 8

Key points:

• Rocuronium (a non-depolarizing neuromuscular blocker) does not trigger MH
• MH is triggered by volatile anesthetics and succinylcholine (depolarizing agent)
• Rocuronium has been successfully used in genetically confirmed MH-susceptible patients under total intravenous anesthesia (TIVA) 7
• Standard rocuronium dosing applies; no dose adjustment needed for MH risk

Critical distinction: Avoid confusing rocuronium with succinylcholine. Succinylcholine is absolutely contraindicated in MH-susceptible patients, while rocuronium is the preferred neuromuscular blocker 8.

Practical Dosing Algorithm

For emergency RSI in adults:

1. Hypotensive patients (SBP <100 mmHg): Use ≥1.4 mg/kg—associated with 94.9% first-attempt success 2
2. Direct laryngoscopy planned: Use ≥1.4 mg/kg for optimal conditions 2
3. Video laryngoscopy planned: 0.6-1.2 mg/kg acceptable (success rates similar across doses) 2
4. Obese patients: Dose on TBW, not LBW 5
5. Standard cases: 1.2 mg/kg provides excellent conditions without cardiovascular compromise 1, 9

Monitoring requirement: Use peripheral nerve stimulation to confirm adequate neuromuscular blockade before intubation attempts when feasible 4, 1.

Reversal availability: Ensure sugammadex is immediately available, though it should not be relied upon as a rescue strategy in "cannot intubate, cannot oxygenate" scenarios 4.